Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,028JPY
11:30pm EDT
Change (% chg)

¥3 (+0.15%)
Prev Close
¥2,025
Open
¥2,011
Day's High
¥2,031
Day's Low
¥2,006
Volume
604,300
Avg. Vol
1,226,662
52-wk High
¥2,087
52-wk Low
¥1,412

4151.T

Chart for 4151.T

About

Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥1,164,497.00
Shares Outstanding(Mil.): 576.48
Dividend: 12.50
Yield (%): 1.24

Financials

  4151.T Industry Sector
P/E (TTM): 56.01 14.29 17.36
EPS (TTM): 36.06 -- --
ROI: 3.19 -7.57 -5.72
ROE: 3.28 -7.17 -5.10

BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab

* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia

Apr 18 2017

BRIEF-Kyowa Hakko Kirin Co Ltd's phase 3 study of mogamulizumab a met its primary endpoint

* Kyowa Hakko Kirin Co Ltd -announced global phase 3 study of mogamulizumab in patients with cutaneous t-cell lymphoma met its primary endpoint

Apr 06 2017

BRIEF-Arqule trial did not meet its primary endpoint of progression free survival

* Trial did not meet its primary endpoint of progression free survival (pfs).

Mar 27 2017

BRIEF-Kyowa Hakko Kirin sets up KYOWA KIRIN FRONTIER Co., Ltd.

Feb 1 Kyowa Hakko Kirin Co Ltd : * Says it set up KYOWA KIRIN FRONTIER Co., Ltd. * Says the capital is 100 million yen Source text in Japanese:https://goo.gl/pbfRNt Further company coverage: (Beijing Headline News)

Feb 01 2017

More From Around the Web

Earnings vs. Estimates